Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology ...

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have received an average rating of “Hold” from the twenty-nine ...

Biogen Inc. closed $118.40 short of its 52-week high ($268.30), which the company achieved on January 3rd.

A Suffolk Superior Court judge dismissed a biomanufacturing company’s lawsuit that claimed disruption caused by a Kendall ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...

Biogen Inc. closed $119.28 below its 52-week high ($268.30), which the company reached on January 3rd.

Specifically, we decided to study Biogen's ROE in this article. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital.